Results 111 to 120 of about 108,790 (321)

Reshaping study design for faster extrapolation‐based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN–NASPGHAN position paper

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Children with inflammatory bowel diseases (IBD) have limited access to the available advanced therapies, given the lengthy gap between adult and pediatric approval. We aimed to review key hurdles for pediatric trials and recommend practical solutions.
Dan Turner, Amit Assa, Mikkel Malham, Shira Yuval Bar‐Asher, Carla Rayan, Jeffrey S. Hyams, Holm H. Uhlig, Brad Pasternak, David C. Wilson, Hilary K. Michel, Lissy de Ridder, Eric Zuckerman, Marina Aloi, Peter Szitanyi, Marla C. Dubinsky, Anne M. Griffiths, Roberto Saldana, Javier Martín‐de‐Carpi, Eytan Wine, Richard K. Russell, Jeremy Adler, Joseph Picoraro   +21 more
wiley   +1 more source

CAQ Corner: Immune‐mediated complications

, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

SPLENIC HOMOTRANSPLANTATION. [PDF]

, 1964
During the past 12 months, five clinical whole-organ splenic homotransplantations have been carried out with the objective of providing active immunologic tissue for the recipient patients.
FUDENBERG, H, MARCHIORO, TL, RIFKIND, D, ROWLANDS, DT, STARZL, TE, WADDELL, WR   +5 more
core  

Pulmonary Mycobacterium avium Infection in a Patient with Crohn's Disease under Azathioprine Treatment [PDF]

, 2014
Tomonori Hirano, Minoru Matsuura, Hiroshi Nakase   +2 more
openalex   +1 more source

Vedolizumab for extraintestinal manifestations in pediatric inflammatory bowel disease: Results from the VedoKids study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Extraintestinal manifestations (EIMs) manifest in 6%‐47% of patients with inflammatory bowel disease (IBD). Here, we characterize the course of EIMs in pediatric patients receiving vedolizumab included in the VedoKids cohort study. This was a subgroup analysis of the pediatric VedoKids cohort, a multicenter, prospective study of children (aged
Giulia D'Arcangelo, Dan Turner, Oren Ledder, Esther Orlanski‐Meyer, Efrat Broide, Maya Granot, Manar Matar, Seamus Hussey, Anat Yerushalmy‐Feler, Christoph Norden, Erasmo Miele, Marina Aloi   +11 more
wiley   +1 more source

Applying Machine Learning Models to Predict Medication Nonadherence in Crohn’s Disease Maintenance Therapy

Patient Preference and Adherence, 2020
Lei Wang,1,* Rong Fan,1,* Chen Zhang,1 Liwen Hong,1 Tianyu Zhang,1 Ying Chen,2 Kai Liu,2 Zhengting Wang,1 Jie Zhong1 1Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of ...
Wang L, Fan R, Zhang C, Hong L, Zhang T, Chen Y, Liu K, Wang Z, Zhong J   +8 more
doaj  

Hepatic growth effects of methylprednisolone, azathioprine, mycophenolic acid, and mizoribine [PDF]

, 1993
Azzarone, A, Francavilla, A, Starzl, TE, Zeng, QH   +3 more
core   +1 more source

Anti‐tumor necrosis factor‐α monotherapy versus combo therapy with immunosuppressant in pediatric inflammatory bowel disease: A real‐life study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives The aim of the study is to evaluate the efficacy of anti‐tumor necrosis factor (TNF)‐α monotherapy versus combination anti‐TNF‐α and immunosuppressive therapy. Methods A single‐center, retrospective, observational study was conducted on inflammatory bowel disease (IBD) children.
Flora Fedele, Massimo Martinelli, Caterina Strisciuglio, Elena Scarpato, Annamaria Staiano, Erasmo Miele   +5 more
wiley   +1 more source

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis [PDF]

, 2016
Antje Timmer, Petrease H Patton, Nilesh Chande, John WD McDonald, John K MacDonald   +4 more
openalex   +1 more source

Therapy de‐escalation in pediatric patients with inflammatory bowel disease in remission: Data analysis from the CEDATA registry

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives There are no standardized criteria about stepping down from combination therapy (immunomodulator and tumor necrosis factor (TNF)‐alpha‐inhibitors) in children with inflammatory bowel disease (IBD) to reduce risk for side effects. Our aim was to describe how de‐escalation has been performed in a large pediatric cohort and to find ...
Sila Cekin, Christoph Huenseler, Serdar Cantez, Ilse Broekaert, Jan de Laffolie, CEDATA‐GPGE® Study Group   +5 more
wiley   +1 more source